• Indazole-Based Glucagon Receptor Antagonists: Synthetic Adva

  2026-07-19

  This study reports the design and synthesis of a novel series of indazole- and indole-based glucagon receptor antagonists (GRAs), targeting improved glycemic control in type 2 diabetes mellitus. Key innovations include targeted modifications of the indazole core and the use of robust synthetic protocols to yield potent, orally active GRAs with favorable pharmacokinetics.

• D-Luciferin Sodium Salt: Precision Bioluminescence in Oncolo

  2026-07-18

  Explore how D-Luciferin sodium salt advances ATP-dependent bioluminescence assays in oncology and cell metabolism research. This in-depth article reveals technical nuances, practical protocol guidance, and new insights inspired by cutting-edge immunotherapy studies.

• Fenipentol (1-Phenyl-1-pentanol): Benchmarks in GI Physiolog

  2026-07-17

  Fenipentol (1-Phenyl-1-pentanol) is a bioactive small molecule with validated roles in gastrointestinal and hepatobiliary research. It acts as a potent choleretic agent and modulates estrogen receptor pathways with defined safety margins. This article delivers evidence-backed insights and protocol guidance for experimentalists.

• ARCA EGFP mRNA (5-moUTP): Engineering Polyadenylated mRNA fo

  2026-07-17

  Explore how ARCA EGFP mRNA (5-moUTP) sets new technical standards for polyadenylated mRNA tools in mammalian cell research. This article offers a deep analysis of mRNA design, stability, and immune evasion, drawing on emerging evidence to guide optimal assay decisions.

• Nutlin-3a: Precision MDM2 Inhibitor for Advanced Cancer Rese

  2026-07-16

  Nutlin-3a empowers researchers with high-fidelity p53 pathway activation and robust apoptosis induction, making it a gold-standard MDM2 inhibitor for cancer biology. This guide delivers actionable workflows, troubleshooting tips, and expert insights to maximize experimental success and translate bench findings into novel therapeutic strategies.

• ERCC1 Deficiency and p53 Status Shape ICL Repair in Lung Can

  2026-07-16

  This study uncovers a synthetic viable phenotype in ERCC1-deficient lung cancer cells exposed to interstrand crosslinking agents, revealing that p53 status critically modulates DNA repair outcomes and drug sensitivity. The findings urge a reevaluation of ERCC1 as a platinum chemotherapy biomarker and offer mechanistic insights for apoptosis signaling research.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guide & Protocols

  2026-07-15

  Cy3 NHS ester (non-sulfonated) enables precise, high-sensitivity fluorescent labeling of proteins, peptides, and oligonucleotides via amine-reactive chemistry. It is best suited for workflows that tolerate organic co-solvents and require orange fluorescence at 555/570 nm. Avoid use with delicate proteins that cannot withstand DMSO/DMF, or where water solubility is essential.

• Z-Ligustilide and Cisplatin: Targeting PLPP1 to Overcome Lun

  2026-07-15

  This study demonstrates that Z-ligustilide, when combined with cisplatin, reverses cisplatin resistance in lung cancer cells by reducing PLPP1-mediated phospholipid synthesis. The findings highlight a novel therapeutic mechanism and suggest new directions for addressing chemoresistance in non-small cell lung cancer.

• Gallein: Applied Workflows for G Protein βγ Subunit Inhibiti

  2026-07-14

  Gallein enables targeted disruption of GPCR signaling for advanced cancer, immunology, and metabolic disease models. This guide details experimental setups, troubleshooting, and best practices for leveraging this potent G protein βγ subunit inhibitor.

• Ibuprofen: Optimized Workflows for Colon Cancer Research

  2026-07-14

  Harnessing Ibuprofen’s dual COX inhibition, this guide translates bench discoveries into robust, reproducible protocols for colon carcinoma studies. Learn how to maximize anti-proliferative impact, streamline cell cycle and apoptosis assays, and troubleshoot solubility and pharmacokinetic challenges with confidence.

• DRD4 Drives Chemo-Resistance via PI3K/Akt/β-Catenin in Liver

  2026-07-13

  This study uncovers a pivotal role for dopamine receptor D4 (DRD4) in fostering chemo-resistance and cancer stem cell-like features in hepatocellular carcinoma (HCC) by activating the PI3K/Akt/β-catenin axis. These findings highlight DRD4 as a potential therapeutic target for overcoming resistance and recurrence in liver cancer.

• Fumagillin: Applied Workflows for Tumor and Antiparasitic Re

  2026-07-13

  Fumagillin, a potent methionine aminopeptidase-2 inhibitor, excels in both antiangiogenic cancer models and targeted antiparasitic assays. This guide details experimental protocols, troubleshooting insights, and how recent research unlocks new cross-domain use-cases for this versatile compound.

• REC8 Stabilizes STING and MAVS to Boost Innate Antiviral Imm

  2026-07-12

  This study uncovers a novel role for the meiosis-associated protein REC8 in innate antiviral immunity. By stabilizing the key signaling adaptors STING and MAVS, REC8 enhances type I interferon responses, suggesting new avenues for modulating the cGAS-STING pathway in viral infection research.

• 10058-F4 C-Myc-Max Dimerization Inhibitor: Protocols & Insig

  2026-07-10

  Explore the scientific foundation and advanced protocols of the 10058-F4 c-Myc-Max dimerization inhibitor. This article reveals how targeting c-Myc/Max interactions unlocks new frontiers in apoptosis assays and translational cancer research.

• Tetraethylammonium chloride (TEAC): Reliable K+ Channel Inhi

  2026-07-09

  This article provides an evidence-based exploration of Tetraethylammonium chloride (SKU B7262) as a reproducible, high-purity K+ channel blocker for cell viability, proliferation, and cytotoxicity assays. Scenario-driven Q&A blocks address real-world challenges, protocol optimization, and vendor selection, highlighting how TEAC from APExBIO supports consistent, quantitative data in advanced ion conduction and vascular research.

453 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page